Notably, studies have highlighted a positive correlation between heightened CD44 levels and adverse prognostic outcomes in various cancers, including breast cancer, colorectal cancer, pancreatic carcinoma, and prostate cancer [12,13,14,15]. The gene discussed is CD44; the disease is prostate carcinoma.